health
Department:
Health
REPUBLIC OF SOUTH AFRICA

SOUTH AFRICAN PRIMARY HEALTHCARE LEVEL ESSENTIAL MEDICINES LIST
CHAPTER 1: ALIMENTARY TRACT
NEMLC RECOMMEDATIONS FOR MEDICINE AMENDMENTS (2020-4 REVIEW CYCLE)

Medicine amendment recommendations, with supporting evidence and rationale are listed below.
Kindly review the medicine amendments in the context of the respective standard treatment guideline (STG).

A: MEDICINE AMENDMENTS

SECTION	MEDICINE/MANAGEMENT	ADDED/DELETED/AMENDED/NOT ADDED/RETAINED
1.1 Gastrointestinal disorders		
1.1.1 Bowel Preparations	Description - dietary restrictions	Guidance amended
1.1.2 Diverticulosis	Description	Amended
	Use of antibiotics	Guidance amended
1.1.3 Gastro-oesophageal reflux disease (GORD)	Title and description	Editorial amendment - dyspepsia added
	General measures	Amended
	Medicine treatment	Editorial amendments
	Medicine treatment - lansoprazole	Deleted
	Medicine treatment - pantoprazole	Added
	Referral	Editorial amendments
1.1.6 Pancreatitis, acute	General measures	Editorial amendments
	Antimicrobial therapy	Editorial amendments
	Co-amoxiclav	Retained for empirical treatment of infected necrosis of the pancreas
1.1.7 Pancreatitis, chronic	General measures	Editorial amendments
	Medicine treatment	Editorial amendments
1.1.8 Peptic ulcer	Medicine treatment	PPI doses and duration amended
	Azithromycin	Treatment duration of three days retained for H.pylori eradication
	Medicine treatment - lansoprazole	Deleted
	Medicine treatment - pantoprazole	Added
1.2 Hepatic Disorders	Description	Editorial amendments
1.2.1 Hepatitis, non-viral	General measures	Editorial amendments
	Medicine treatment - Lyophilised plasma	Guidance added
	Medicine treatment – Fresh frozen plasma:	Guidance added
	Medicine treatment – Vitamin K, IV	Guidance added
1.2.2 Liver failure, acute	General measures	Editorial amendments
	Antiviral therapy – acute treatment	Not added
1.2.3 Portal hypertension and cirrhosis	General measures	Editorial amendments
	Variceal bleeding - octreotide	Not added
	Medicine treatment - ascites	Editorial amendments
	Medicine treatment – tense ascites	Editorial amendments
	Medicine treatment – refractory ascites	Editorial amendments
	Medicine treatment – oesophageal varices	Carvedilol – not added – on therapeutic interchange database
	Referral	Editorial amendments
1.2.4 Hepatitis, viral	Description	Editorial amendments
-1.2.4.1 Hepatitis B, acute	General measures	Editorial amendments
	General measures	Add cross-reference to Hep B vaccination
	Hepatitis B virus prophylaxis following exposure	Amended
-1.2.4.2 Hepatitis B, chronic (Non-HIV coinfection)	Hepatitis B virus prophylaxis following exposure	Amended
	Tenofovir disoproxil furmarate (TDF) eGFR > 50mL/min	Retained
	Tenofovir alafenamide (TAF) eGFR >50mL/min	Added to TI database
	Tenofovir alafenamide (TAF) – 15-50mL/min (or on haemodialysis)	Added

	Monitoring whilst on tenofovir:	Editorial amendments
1.3 Diarrhoea		
1.3.1 Cholera	*Ciprofloxacin*	*Dose and duration of treatment amended*
	Ringers lactate	*Added*
1.3.2 Dysentry (acute inflammatory diarrhoea)	Antibiotic therapy	Editorial amendments
1.3.3 Diarrhoea, acute non-inflammatory	Medicine treatment –loperamide:	Dose amended
1.3.4 Clostridium difficile diarrhoea	Title	Editorial amendments
	Mild-moderate infection - vancomycin	Not added
	Fulminant infection – rectal vancomycin	Not added

1.1.1 BOWEL PREPARATIONS

Description – dietary restrictions: *Guidance amended*

The following editorial amendments were made in line with the European Society for Gastrointestinal Endoscopy (ESGE)[1] Bowel preparation for colonoscopy guidelines.

Bowel preparation is essential for colonoscopy.
Split-dose (half the dose the night before and half the dose on the day of colonoscopy) bowel cleanser ~~and no dietary restriction seems to provide better quality colon cleansing than single doses with a liquid diet on the day preceding colonoscopy. a low residue diet should be commenced the day before.~~ and a low residue diet should be commenced the day before.

1.1.2 DIVERTICULOSIS

Description: *Amended*

Medicine treatment – antibiotics: *Guidance amended*

External comment was received to consider less aggressive use of antibiotics for the management of mild diverticulitis. The Committee were of the view that the evidence is still evolving with regard to the appropriate patient cohorts for whom use of antibiotics is clearly indicated. Amendments were made to the guidance on medicine management as tabulated below. The Committee further recommended that the STG on the management of diverticulosis be prioritized for the next review cycle.

AMENDED FROM:
DESCRIPTION
Diverticulosis can be complicated by haemorrhage or diverticulitis. Acute diverticulitis is inflammation of diverticulae, usually accompanied by polymicrobial infection.

MEDICINE TREATMENT
Total duration of antibiotic therapy is 10 days, depending on clinical response.

AMENDED TO:
DESCRIPTION
Diverticulosis can be complicated by haemorrhage or diverticulitis. Acute diverticulitis is inflammation of diverticulae, uncommonly accompanied by polymicrobial infection.

MEDICINE TREATMENT
Not all patients require antibiotics, if antibiotic treatment is required, the total duration is ten days depending on clinical response.

1.1.3 GASTRO-OESOPHAGEAL REFLUX (GORD)

Title and description: *editorial amendment*

External comment received that the title for Section 1.1.3 should be amended to include dyspepsia and a general description for dyspepsia be included. The following editorial amendments have been made:

[1] Hassan C et al. Bowel preparation for colonoscopy: European Society for Gastrointestinal Endoscopy (ESGE)[1] guidelines: update 2029. DOI https://doi.org/10.1055/a-0959-0505. Published online: 2019 | Endoscopy

1.1.3 GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) AND DYSPEPSIA

K21.0/K21.9/K22.7, K30

DESCRIPTION

GORD is a disorder which develops as a consequence of the reflux of gastric and duodenal contents into the oesophagus. It is usually characterised by heartburn and regurgitation.

Dyspepsia is the sensation of epigastric discomfort. It may be a feature of potentially severe diseases such as peptic ulcer disease or gastric cancer. It may also be a symptom H pylori gastritis or NSAID gastritis.

Intermittent indigestion, heartburn or dyspepsia may be associated with:

- » use of NSAIDs e.g. aspirin, ibuprofen, pain powders
- » spicy food, alcohol, carbonated drinks
- » smoking

Complications that may develop in severe GORD ~~disease~~ are strictures, ulceration, Barrett's oesophagus and adenocarcinoma of the oesophagus. Two thirds of patients have a normal endoscopy which is termed non-erosive reflux disease (NERD) or non-ulcer dyspepsia (NUD) depending on the predominant symptom.

General measures: *amended*

The general measures have been aligned with the recommendations in Table 3 of the American College of Gastroenterology Clinical Guidelines[2]. Furthermore, the age threshold for referral for an endoscopy has been amended from older than 45 years to older than 60 years, in line with the ACG management of dyspepsia guidelines[3] and a local study by Cheddie et al.[4]

AMENDED FROM:	AMENDED TO:
GENERAL MEASURES » Stop smoking. » Limit alcohol intake. » Eat small frequent meals. » Avoid late night meals. » Check haemoglobin. » Stop the use of potential ulcerogenic medicines e.g. NSAIDs. All patients with alarm symptoms, i.e. weight loss, haematemesis or melaena, dysphagia, or anaemia, chest pain or older than 45 years of age should have an endoscopy.	**GENERAL MEASURES** » Stop smoking. » Limit alcohol intake. » Eat small frequent meals. » Avoid late night meals. » Avoid fatty meals. » Avoid carbonated beverages. » Lose weight if overweight. » Sleep with upper body elevated. » Sleep on the left side. » Avoid excessive exercise » Stop the use of potential ulcerogenic medicines e.g. NSAIDs. » If pale, check haemoglobin and refer if anaemic All patients with alarm symptoms, i.e. weight loss, haematemesis or melaena, dysphagia, or anaemia, chest pain or patients older than 60 years of age with new onset dyspepsia should have an endoscopy.

Medicine treatment – lansoprazole: Delete

Medicine treatment – pantoprazole: Added

Lansoprazole has been replaced with pantoprazole as the PPI of choice in line with the latest tender (Contract circular HP09-2023SD). Pantoprazole 40mg and 20mg is listed on the therapeutic interchange database as an alternative to lansoprazole 30mg and 15mg respectively.

Medicine treatment: *editorial amendments*

Guidance included on when it would not be appropriate to reduce the dose of proton pump inhibitors (PPIs) as tabulated below:

AMENDED FROM:

Proton pump inhibitors (PPIs)

A trial with a PPI confirms acid-related disease. Only if no alarm symptoms:

- PPI, e.g.:
- Lansoprazole, oral, 30 mg daily for 4 weeks.
  - Ensure adherence to promote healing.

[2] Katz PO et al. ACG Clinical Guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2022;117:27–56. https://doi.org/10.14309/ajg.0000000000001538; published online November 22, 2021.

[3] Moayyedi PM, Lacy BE, Andrews CN, et al. ACG and CAG clinical guideline: Management of dyspepsia. Am J Gastroenterol. 2017 Jul;112(7):988-1013. http://doi.org/10.1038/ajg.2017.154

[4] Cheddie S et al. Age is a predictor of significant endoscopic findings in dyspepsia patients in South Africa. Southern African Journal of Surgery 2020; 58(1):14-17 http://dx.doi.org/10.17159/2078-5151/2020/v58n1a2814.

Recurrence of symptoms
After endoscopic confirmation of disease:
- PPI, e.g.:
- Lansoprazole, oral, 30 mg daily.
  - Decrease dose of PPI after 4 weeks, e.g: omeprazole, oral, 10 mg daily.

Barrett's oesophagus K22.7
Restart PPI:
- PPI, e.g.:

Lansoprazole, oral, 30 mg daily

AMENDED TO:
New onset symptoms
Empiric therapy with a proton pump inhibitor (PPI) may be initiated **in the absence of alarm symptoms** (see referral section). Improvement of symptoms confirms acid-related disease.
- PPI, e.g.:
- Pantoprazole, oral, 40 mg daily for 4 weeks.
  - Ensure adherence to promote healing.

Recurrence of symptoms
After endoscopic confirmation of disease:
- PPI, e.g.:
- Pantoprazole, oral, 40 mg daily.
  - Decrease dose of PPI after 4 weeks, e.g: pantoprazole, oral, 20 mg daily except for severe endoscopic GORD (Grade C or D LA classification) and Barret's oesophagus or specific advice from the endoscopist.

Barrett's oesophagus K22.7
Restart PPI:
- PPI, e.g.:
- Pantoprazole, oral, 40 mg daily.

Referral: *editorial amendments*
The following editorial amendments were made to the referral criteria:

REFERRAL
Discuss with a specialist:
» young patients who are PPI dependent and will require life-long therapy;
» patients unable to take PPIs;
» patients requiring high doses of PPIs;
» patients with large hiatus hernias and "volume reflux";
» a rolling hiatus hernia with obstructive symptoms requires surgery;
» All patients with alarm symptoms. ~~Alarm features that may be suggestive of gastrointestinal malignancy:~~
  ~~— New onset dyspepsia in patient > 60 years~~
  — Evidence of gastrointestinal bleeding,
  — Evidence of gastrointestinal bleeding,
  — Iron deficiency anaemia,
  — Anorexia,
  — Unexplained weight loss,
  — Dysphagia,
  — Odynophagia (painful swallowing),
  — Persistent vomiting, and haematemesis and malaena,
  — Gastrointestinal cancer in a first-degree relative.

1.1.6 PANCREATITIS, ACUTE

General measures: *Editorial amendment*
The following statement was removed from the STG as no longer appropriate: *'Nasogastric suction when persistent vomiting or ileus occurs,'* in line with the European Society for Clinical Nutrition and metabolism (ESPEN) guideline[5]

Antimicrobial therapy: *Editorial amendment*
The following editorial amendment was made to reflect more appropriate medical terminology: amended from 'abscess of the pancreas' to 'infected necrosis of the pancreas'.

[5] Arvanitakis, Met al (2020). ESPEN guideline on clinical nutrition in acute and chronic pancreatitis. Clinical Nutrition, 39(3), 612-631. https://doi.org/10.1016/j.clnu.2020.01.004

Infected necrosis of the pancreas – empirical treatment: *Co-amoxiclav retained*
External comment was received that co-amoxiclav may not be the best choice of antibiotic for infected necrosis of the pancreas. The Committee agreed that co-amoxiclav be retained as empirical treatment until there is clear evidence to support an alternative. Patients with infective pancreatitis should be referred for specialist care.

1.1.7 PANCREATITIS, CHRONIC

General measures: *Editorial amendment*
The following statement was deleted: '*Elemental diets (i.e. parenteral or enteral nutrition) in chronically debilitated patients',* as elemental diets are no longer recommended.

Medicine treatment: *Editorial amendments*
The following editorial amendments were made and aligned with European Society for Clinical Nutrition and metabolism (ESPEN)[6] guideline.

MEDICINE TREATMENT
Treatment is aimed at:
- » pain,
- » exocrine dysfunction (malabsorption, and diarrhoea)
- » endocrine function. See section 8.5.2: Type 1 Diabetes mellitus.

Malabsorption
~~Start treatment when >7 g (or 21 mmol) fat in faeces/24 hours while on a 100 g fat/day diet.~~
~~Reduce dietary fat to <25 g/meal.~~
Supplementation of fat-soluble vitamins may be indicated.

- Pancreatic enzyme replacement e.g. Lipase, oral, equivalent to lipase 30 000 units per day, in divided doses with meals.
- Pancreatic enzyme replacement therapy is titrated until there is symptom control and is taken during meals and with snacks.

~~**Aim for symptom control and/or 5% of normal faecal fat output**~~

1.1.8 PEPTIC ULCER

H.pylori positive - proton pump inhibitors (PPIs): *Duration of therapy amended*
H.pylori negative – proton pump inhibitors (PPIs): *Dose and duration amended*
H.pylori eradication – azithromycin*: Treatment duration retained*

The duration of twice daily PPI therapy has been amended to align to the NEMLC approved NDoH evidence summary for H.pylori eradication[7] (final NEMLC decision as tabulated below). The maximum duration of therapy with the ongoing once daily dosing is aligned to the recommended registered duration of therapy for gastric and duodenal ulcers respectively.

[6] Arvanitakis, Met al (2020). ESPEN guideline on clinical nutrition in acute and chronic pancreatitis. Clinical Nutrition, 39(3), 612-631. https://doi.org/10.1016/j.clnu.2020.01.004
[7] NDoH Evidence Review. H.pylori eradication. 4 June 2020

Type of recommendation	We recommend against the option and for the alternative	We suggest not to use the option or to use the alternative	We suggest using either the option or the alternative	We suggest using the option	We recommend the option
	X	☐	☐	☐	☐

Recommendation:

Based on this evidence review, the Adult Hospital Level Committee reccomends that azithromycin be retained as part of the recommended triple therapy for eradicationof *Helicobacter pylori*. However, clarithromycin could be considered as a therapeutic alternative where there are supply constraints with azithromycin.

Duration of therapy for clarithromycin (as part of triple therapy) should be extended for 14 days, whilst azithromycin could be extended to 10 days (as the elimination half-life is 68 to 72 hours).

Of note is that an increase in resistance of metronidazole would limit the therapeutic efficacy of triple therapy in penicillin-allergic pateients – more local antibiotic susceptibility data is required.

Empiric therapy should not be instituted without diagnostics and treatment failure should be guided by sensitivity and culture.

Rationale: Available evidence suggests that azithromycin is comparable to clarithromycin in terms of efficacy; though evidence is of low to moderate quality. Increasing duration of therapy to 14 days has been shown to improve eradication rates of proton pump inhibitor + amoxicillin + clarithromycin (PAC) and proton pump inhibitor + amoxicillin + metronidazole (PAM) regimens. However, local sensitivity patterns is required to guide combination triple therapy for *Helicobacter pylori* eradication.

Level of Evidence: II Moderate quality meta-analyses, Antibiotic susceptibility studies, Expert opinion

NB: PLEASE SEE BELOW FOR FINAL NEMLC RECOMMENDATION.

Review indicator: Price and antimicrobial susceptibility data

Evidence of efficacy	Evidence of harm	Price reduction
X		X

VEN status: n/a

Vital	Essential	Necessary

Monitoring and evaluation considerations: Resistance patterns

Research priorities: Resistance patterns

NEMLC MEETING OF 11 JUNE 2020:

NEMLC DISCUSSION:

Azithromycin: Despite the biological elimination half-life of 68 to 72 hours, tissue concentrations were reported to be as long as 14 days. Thus, the NEMLC recommended that the duration of therapy of azithromycin be retained at 3 days, and not be extended to 10 days.

- *Sampson et al.*[1] evaluated whole blood and intracellular concentrations (peripheral blood mononuclear cells and polymorphonuclear cells) for 21 days after a single dose of azithromycin (250 mg to 1000 mg). Concentrations in cells were measured as two orders of magnitude higher intracellularly than in blood and declines very slowly over 21 days.

Medicine treatment – lansoprazole: Delete

Medicine treatment – pantoprazole: Added

Lansoprazole has been replaced with pantoprazole as the PPI of choice in line with the latest tender (Contract circular HP09-2023SD). Pantoprazole 40mg and 20mg is listed on the therapeutic interchange database as an alternative to lansoprazole 30mg and 15mg respectively.

For H.pylori negative patients, the dose of PPI has been amended to align to the registered once daily dose with the duration of therapy for gastric and duodenal ulcers amended accordingly. Amendments to the STG are as tabulated below:

AMENDED FROM:	AMENDED TO:
1.1.8 PEPTIC ULCER	**1.1.8 PEPTIC ULCER**
DESCRIPTION Ulcer in the stomach mucosa (gastric ulcer: GU) or first few centimetres of the duodenum (duodenal ulcer: DU), which penetrates into or through the muscularis mucosa. Diagnosis is made after endoscopy, as all GUs require biopsy to exclude malignancy. Patients with GUs and complicated DUs, those that have bled, perforated or are recurrent, must be rescoped at appropriate intervals until the ulcer has healed. *H. pylori* can be assessed at scope by rapid urease testing (RUT) or biopsy.	**DESCRIPTION** Ulcer in the stomach mucosa (gastric ulcer: GU) or first few centimetres of the duodenum (duodenal ulcer: DU), which penetrates into, or through the muscularis mucosa. Diagnosis is made after endoscopy as all GUs require biopsy to exclude malignancy.
GENERAL MEASURES Advise patient to avoid ulcerogenic medications, e.g. NSAIDs. Advise patient to stop smoking and drinking alcohol. Dietary advice by dietician.	**GENERAL MEASURES** » Advise patient to avoid ulcerogenic medications, e.g. NSAIDs. » Advise patient to stop smoking and drinking alcohol. » Dietary advice by dietician. » Patients with GUs and complicated DUs, those that have bled, perforated or are recurrent, must be rescoped at appropriate intervals until the ulcer has healed. *H. pylori* can be assessed at scope by rapid urease testing (RUT) or biopsy.
MEDICINE TREATMENT ***H. pylori* +ve** The vast majority of GUs and DUs are associated with *H. pylori* infection and eradication therapy is indicated if infection is present. This will greatly reduce the rate of recurrent ulceration. Empiric eradication of *H. pylori* is not recommended. **Proton pump inhibitors (PPIs)** ▪ PPI, e.g.: • Lansoprazole, oral, 30 mg 12 hourly. ○ Duodenal ulcer: for 7 days. ○ Gastric ulcer: for 28 days. **AND** <u>*H. PYLORI* ERADICATION:</u> K25.0-7/K25.9/K26.0-7/K26.9/K27.0-7/K27.9 + (B96.8) • Amoxicillin, oral, 1 g 12 hourly for 7 days. **OR** <u>For severe penicillin allergy:</u> (Z88.0) • Azithromycin, oral, 500 mg daily for 3 days. **AND** • Metronidazole, oral, 400 mg 12 hourly for 7 days. Failure of *H. pylori* eradication: Discuss with specialist. ***H. pylori* –ve** These are usually a consequence of NSAID use. Stop NSAID until ulcer has healed. If patient is unable to stop NSAID, refer to specialist. ▪ PPI, e.g.: • Lansoprazole, oral, 60 mg daily. ○ Duodenal ulcer: for 14 days. ○ Gastric ulcer: for 28 days. **Resistant disease** Ulcer not healing. High-risk patients, i.e. poor surgical risk and the elderly or concomitant disease. Maintenance therapy: ▪ PPIs, e.g.: • Lansoprazole, oral, 30 mg daily. Specialist initiated.	**MEDICINE TREATMENT** ***H. pylori* positive:** The vast majority of GUs and DUs are associated with *H. pylori* infection and eradication therapy is indicated if infection is present. This will greatly reduce the rate of recurrent ulceration. Empiric eradication of *H. pylori* **is not recommended**. <u>*H. pylori* eradication:</u> K25.0-7/K25.9/K26.0-7/K26.9/K27.0-7/K27.9 + (B98.0) • Amoxicillin, oral, 1 g 12 hourly for 14 days. **OR** <u>For severe penicillin allergy:</u> (Z88.0) • Azithromycin, oral, 500 mg daily for 3 days. **AND** • Metronidazole, oral, 400 mg 12 hourly for 14 days. <u>Proton pump inhibitors (PPIs):</u> ▪ PPI, e.g.: • Pantoprazole, oral, 40 mg 12 hourly for 14 days. Continue with PPI therapy as follows: ▪ PPI, e.g.: • Pantoprazole, oral, 40 mg daily. ○ Duodenal ulcer: for up to 2 weeks ○ Gastric ulcer: for up to 6 weeks ***H. pylori* negative:** » These are usually a consequence of NSAID use. » Stop NSAID until ulcer has healed. » If patient is unable to stop NSAID, refer to specialist for guidance. ▪ PPI, e.g.: • Pantoprazole, oral, 40 mg daily. ○ Duodenal ulcer: for up to 4 weeks ○ Gastric ulcer: for up to 8 weeks. **Resistant disease** » Ulcer not healing. » High-risk patients, i.e. poor surgical risk and the elderly or concomitant disease. <u>Maintenance therapy:</u> ▪ PPIs, e.g.: • Pantoprazole, oral, 40 mg daily. Specialist initiated. **REFERRAL** » Failure of *H. pylori* eradication: Discuss with specialist.

Treatment duration of azithromycin: External comment received on whether the treatment duration of azithromycin should be extended for longer than three days for H.pylori eradication. The treatment duration of 3 days was retained, based on the previously updated NEMLC recommendation (June 2020)[8] during which it was noted that despite the biological elimination half-life of 68 to 72 hours, tissue concentrations were reported to be as long as 14 days. A summary of the NEMLC recommendation is tabulated below:

NEMLC RECOMMENDATIONS: NEMLC recommended that the duration of therapy for azithromycin be retained as 3 days. For other antibiotics, amoxicillin and metronidazole, duration of therapy to be extended for 14 days for the eradication of *H.pylori.* Clarithromycin was cost-prohibitive and could be considered as a therapeutic alternative where there are supply constraints with azithromycin. And, more substantial local antimicrobial susceptibility studies were required to confirm metronidazole resistance in our local setting. *Rationale:* Despite an elimination half-life of 68 to 72 hours, azithromycin tissue concentrations have been shown to be adequate (>1 mg/L) 21 days after administration of a single dose of 1.5 g or 3 day course of 500 mg per day. For other antibiotics (amoxicillin and metronidazole), 14-day duration of therapy is recommended as a Cochrane review showed that *H. pylori* eradication rates for 14-days PPI triple therapy was significantly higher than for 7 days (*H. pylori* persistence, regardless of regimen and dose: RR 0.66 (95% CI 0.6 to 0.74), NNT 11 (95% CI 9 to 14). **Level of Evidence: I Metaanalysis and systematic review, Pharmacokinetic studies**	

1.2 HEPATIC DISORDERS

Description: *Editorial amendment*
An editorial amendment was made to include 'non-alcoholic fatty liver disease' as a cause of hepatitis.

1.2.1 HEPATITIS, NON-VIRAL

General measures: *Editorial amendment*
An editorial amendment was made in respect of managing patients with hepatic encephalopathy and the intake of protein was corrected as grams of protein per day, as tabulated below:

With clinical monitoring of hepatic encephalopathy, maintain 1 to 1.5 g~~mg~~/kg daily protein intake.

Medicine treatment - Lyophilised plasma: *Guidance added*
Medicine treatment – Fresh frozen plasma: *Guidance added*
Medicine treatment – Vitamin K, IV: *Guidance added*
Dosing and administration guidance on the use of vitamin K, lyophilised plasma and Fresh Frozen Plasma has been included in consultation with a hepatic specialist. The use of platelets for the management of bleeding to be considered for prioritisation in the next review cycle.

Updates to the chapter as tabulated below:

AMENDED FROM:	AMENDED TO:
1.2.1 HEPATITIS, NON-VIRAL **MEDICINE TREATMENT** If the patient is bleeding, check INR and correct coagulopathy with: • Lyophilised plasma **or** FFP Parenteral Vitamin K should be provided and the INR reassessed.	**1.2.1 HEPATITIS, NON-VIRAL** **MEDICINE TREATMENT** **If the patient is jaundiced with a prolonged INR (INR>2)** • Vitamin K1, IV, 10 mg ○ Administer as a slow IV injection. ○ Do not dilute or mix with other injectables. **If the patient is bleeding, give** • Lyophilised plasma, IV, 15mL/kg over 20-30 minutes. **OR** • Fresh Frozen Plasma, IV, 15mL/kg over 20-30 minutes. **AND** Discuss further management with a specialist.

[8] NDoH Evidence Review. H.pylori eradication. 4 June 2020

1.2.2 LIVER FAILURE, ACUTE

General measures: *Editorial amendment*

Editorial amendments were made to the STG as tabulated below. The use of parenteral vitamin K1 to be considered for prioritisation for review in the next review cycle.

- Protein restriction is indicated for encephalopathy, however, severe protein restriction may accentuate catabolism. Use increments of 20 g protein per day aiming for 1g/kg/day as tolerated.
- Exclude GI bleed and infection. ~~as a precipitant.~~
- If the patient is bleeding, check INR and correct coagulopathy with FFP or lyophilised plasma. ~~Routine administration of parenteral vitamin K_1 is of unproven value.~~

Acute liver failure – antiviral therapy: *Not added*

The use of antiviral therapy for the management of acute liver failure or progressive synthetic dysfunction was not supported as no compelling evidence was identified to support the use of antivirals for these indications.

1.2.3 PORTAL HYPERTENSION AND CIRRHOSIS

General measures: *Editorial amendment*

An editorial amendment was made in respect of managing patients with hepatic encephalopathy with the intake of protein being corrected as grams of protein per day, as tabulated below.

Hepatocellular carcinoma was added to the list of potential diagnoses to be excluded.

Encephalopathy: with acute HE, protein restrict (ideally under advice of dietician), otherwise 1–1.5 g~~mg~~/kg protein per day. Exclude infection, high protein load, occult bleed, sedatives and electrolyte disturbances and hepatocellular carcinoma

Variceal bleeding: *octreotide not added*

The use of octreotide for the management of variceal bleeds has not been added to the EML as it is yet to be reviewed by the Tertiary Expert Review Committee for potential consideration for inclusion on the Tertiary EML.

Medicine treatment - ascites: *editorial amendments*

The following editorial amendments were made to the STG:

Ascites R18

- Diagnostic paracentesis if indicated
- Single morning dose of oral spironolactone, oral 100 mg and furosemide, oral, 40 mg.
  - Increase the dose by 100 mg and 40 mg, respectively, every 3–5 days, to a maximum dose of 400 mg spironolactone and 160 mg of furosemide depending on serum Na^+, K^+, urea and creatinine.
  - Spironolactone may cause hyperkalaemia.
  - Rapid fluid shifts may precipitate acute liver and/or renal failure.

Medicine treatment – Tense ascites: *editorial amendments*

The following editorial amendments were made to the STG:

Albumin replacement ~~should be considered~~ must be given if ≥5 L of fluid is drained by paracentesis, or if there is pre-existing renal dysfunction:

Medicine treatment – Refractory ascites: *editorial amendments*

The following editorial amendments were made to the STG:

Albumin replacement ~~should be considered~~ must be given if ≥5 L of fluid is removed removed by paracentesis:

Oesophageal varices: *carvedilol not added*

Propranolol included on the therapeutic interchange database as example of class the therapeutic class of beta blockers for the management of oesophageal varices.

Referral: *editorial amendment*

Endoscopic variceal ligation has been added an option for referral to a specialist unit for further management.

1.2.4 HEPATITIS, VIRAL

Description: *editorial amendment*
The description has been amended to include hepatitis D i.e. *'Hepatitis caused by one of the hepatotropic viruses, hepatitis A, B, C, D and E.'*

1.2.4.1 HEPATITIS B, ACUTE

General measures: *editorial amendment*
The STG has been clarified to indicate that patients who are non-immune (negative for surface hepatitis B antibodies), should receive hepatitis B immunisation.
A cross reference to the AH Chp 9 : Infections chapter Section 9.2 Adult vaccination chapter has been added.

Medicine treatment – hepatitis B virus prophylaxis following exposure: *Amended*
Home-based or family caregivers have been included as individuals at high risk for exposure to hepatitis B – they should therefore be screened and vaccinated against hepatitis B.

AMENDED FROM:
Hepatitis B virus: prophylaxis following exposure e.g. needle stick injury
S61.0 + (W46.22+Z20.5+Z29.8)
Persons at risk can be protected by passive immunisation with hyper immune serum globulin prepared from blood containing anti-HBs.
It is essential that all categories of healthcare workers (HCW) who are at risk of exposure, including cleaning staff, be fully vaccinated against hepatitis B.

AMENDED TO:
Hepatitis B virus: prophylaxis following exposure e.g. needle stick injury
S61.0 + (W46.22+Z20.5+Z29.8)
Persons at risk can be protected by passive immunisation with hyper immune serum globulin prepared from blood containing anti-HBs.
It is essential that all categories of healthcare workers (HCW) at risk of contact with bodily fluids, including cleaning staff, home-based or family caregivers are screened and fully vaccinated against hepatitis B if non-immune.

1.2.4.2 HEPATITIS B, CHRONIC (NON-HIV COINFECTION)

Hepatitis B screening and immunization for close family contacts and caregivers: *Amended*
The STG has been amended to include guidance for screening and vaccination against hepatitis B for at risk individuals including home-based or family caregivers. The following statement has been added to the STG:

Screen all categories of healthcare workers (HCW) at risk of contact with bodily fluids, including cleaning staff, home-based or family caregivers and vaccinate against hepatitis B if not immune (see Section 24.1.5 management of close contacts of patients with hepatocellular carcinoma).

Tenofovir disoproxil furmarate (TDF) – eGFR > 50mL/min: *Retained*
TDF 300mg daily has been retained on the EML for the management of chronic hepatitis B (non-HIV coinfection) in patients woithout renal impairment.

Tenofovir alafenamide (TAF) – eGFR > 50mL/min: *Added to TI database*
TDF & TAF - Therapeutic Interchange: *Added*
The NEMLC supported the inclusion of TDF 300mg daily and TAF 25mg daily on the TI database for the management of chronic hepatitis B (non-HIV confection) in patients without renal impairment i.e. eGFR > 50mL/min.

Section (Description)	Indication	Therapeutic Class	INN	Strength	Unit	Formulation
Chronic hepatitis B (non-HIV confection)	Treatment – eGFR > 50mL/min	Antivirals – nucleoside reverse transcriptase inhibitors	Tenofovir disoproxil fumarate (TDF)	300	mg	Oral
Chronic hepatitis B (non-HIV confection)	Treatment – eGFR > 50mL/min	Antivirals – nucleoside reverse transcriptase inhibitors	Tenofovir alafenamide (TAF)	25	mg	Oral

Tenofovir alafenamide (TAF) - eGFR 15-50mL/min (or on haemodialysis): *Added*

Following the NEMLC decision to include TAF in the EML for PLHIV and hepatitis B coinfection with renal impairment (*refer to NEMLC report for AH Chp 10 HIV*) in accordance with the evidence review undertaken in PLHIV[9], the NEMLC recommended a uniform approach to managing patients with chronic hepatitis B and renal impairment (eGFR <50mLs/min), irrespective of HIV status – refer to Addendum 1 of the evidence review on the Knowledge Hub[10] or as included below. It is anticipated that the cohort of patients with chronic hepatitis B and eGFR <50mLs/min, without HIV coinfection, will be a relatively small number of patients.[11] The use of tenofovir disoproxil furmarate (TDF) 300mg daily will be retained in the EML for managing chronic hepatitis B in HIV negative patients, who present with a eGFR>/= 50ml/min. To note, TAF monotherapy can be safely administered from eGFR 15mLs/min, however for PLHIV who are likely to receive TAF in a fixed dose combination with FTC (emtricitabine) or 3TC (lamivudine), an eGFR < 30 mLs/min would be a contraindication to use. The STG has been amended as tabulated below:

AMENDED FROM:

MEDICINE TREATMENT

- Tenofovir, oral, 300 mg daily, if estimated CrCl >50 mL/minute.

REFERRAL

Failure of or contraindications to tenofovir.

AMENDED TO:

MEDICINE TREATMENT

If eGFR > 50mL/min/1.75m^2

- Tenofovir disoproxil fumarate (TDF), oral, 300 mg daily

If eGFR 15-50mL/min/1.75m^2 (or on haemodialysis)

- Tenofovir alafenamide (TAF), oral, 25 mg daily

REFERRAL

Failure of, or contraindications to tenofovir. disoproxil fumarate and tenofovir alafenamide.

Monitoring whilst on tenofovir: *Editorial amendments*

Guidance on monitoring requirements while on tenofovir treatment has been aligned to the NDoH viral hepatitis guideline[12] and amended as tabulated below:

AMENDED FROM:

MONITORING WHILST ON TENOFOVIR

Baseline	FBC+diff, ALT, INR, urine protein, serum phosphate and serum creatinine
Week 4 and every 12 weeks	FBC+diff, ALT
Week 4	INR
Week 4, then at 3, 6 and 12 months after initiation and every 12 months thereafter if on TDF	Serum creatinine
Every 6 months	HBeAg-positive patients: HbsAg after anti-HBe seroconversion HBeAg-negative patients: HBsAg with persistently undetectable HBV DNA
Every 12 months	HBeAg-positive patients: HBeAg, anti HBe
HBeAg-positive patients: 12 months after HBeAg seroconversion	HBV DNA levels

AMENDED TO:

Monitoring whilst on tenofovir

Monitoring test	When to perform test
Serum phosphate and urine protein	Baseline
INR	Baseline, Week 4
Serum creatinine	All patients: Baseline

[9] NDoH Evidence Summary: Use of TAF for adults with HIV. V4_14 March 2024.

[10] NDoH Evidence Summary: Use of TAF for adults with HIV. V5_1 July 2024.

[11] The inclusion of TAF 25mg on the EML for the management of hepatitis B in patients with renal impairment and non-HIV coinfected, is subject to review once the price of TAF 25mg is confirmed.

[12] *National Department of Health, National guidelines for the management of viral hepatitis, 2019. Available at www.health.gov.za*

	Patients on TDF: Week 4, then 3 months, 6 months, and 12 months after initiation; then, every 12 months thereafter.
ALT	Baseline, Week 4, and every 12 weeks thereafter
FBC+Diff	Baseline, Week 4, and every 12 weeks thereafter
HBeAg and Anti-HBe	HBeAg-positive patients: Every 12 months
HBsAg	HBeAg-positive patients: HBsAg every 6 months after anti-HBe seroconversion HBeAg-negative patients: HBsAg every 6 months with persistently undetectable HBV DNA
HBV DNA levels	HBeAg-positive patients: 12 months after HBeAg seroconversion

Table 1.3: Monitoring tests whilst on tenofovir

Adapted from: National Department of Health, National guidelines for the management of viral hepatitis, 2019. Available at www.health.gov.za

1.3.1 CHOLERA

Following consultation with the NICD and the NDoH program guideline team, the STG on the management of cholera has been amended as tabulated below.

Ciprofloxacin dose and duration of treatment: *Amended*

Guidance on the dosing and duration of ciprofloxacin treatment for cholera has been amended in line with the GTFCC (Global Task Force on Cholera Control) guideline[13] for adults.

Fluid replacement – ringers lactate: *Added*

A number of international guidelines[14,15,16] recommend ringers lactate as the preferred IV fluid for replacement therapy in patients infected with cholera, due to the inclusion of the electrolytes potassium and bicarbonate. In the absence of good quality evidence demonstrating the superiority of Ringer's lactate over sodium chloride 0.9%, it was agreed that both ringers lactate and sodium chloride be recommended as options for IV fluid replacement in patients infected with cholera, with Ringer's lactate listed as the preferred option particularly when routine monitoring of potassium and other electrolytes is not possible e.g. at the primary healthcare level of care. Retaining sodium chloride 0.9% on the EML will avert delays with initiating IV fluid should Ringer's lactate not be readily available.

AMENDED FROM:

GENERAL MEASURES

Rehydration is the cornerstone of management. This should be done with oral rehydration solution (ORS) unless the patient is vomiting or profoundly dehydrated.

MEDICINE TREATMENT

- Ciprofloxacin, oral, 500 mg 12 hourly for 3 days.
  - Adjust antibiotic choice, according to the sensitivity of the isolate responsible for the local epidemic.

AMENDED TO:

GENERAL MEASURES

Rehydration is the cornerstone of management. Oral rehydration is preferred.

MEDICINE TREATMENT

Oral rehydration solution (ORS) by mouth or nasogastric tube.

[13] Global Task Force on Cholera Control. October 2019

[14] Harris JB et al. Cholera (NIH). Lancet. 2012 June 30; 379(9835): 2466–2476. doi:10.1016/S0140-6736(12)60436-X

[15] Nelson EJ et al. Cholera outbreak training and shigellosis program (COTSPROGRAM). V2 may 2018

[16] Global Task Force on Cholera Control. October 2019

If enteral administration not possible, e.g., patient is vomiting, profoundly dehydrated, or stuporous:
IV treatment:
Ringers lactate, IV (preferred)

OR

Sodium chloride, 0.9%, IV.

AND

- Ciprofloxacin, oral, 1 gram as a single dose
  - Adjust antibiotic choice, according to the sensitivity of the isolate responsible for the local epidemic.

NOTE: Dextrose 5% should not be used for fluid replacement in patients with cholera as it does not contain electrolytes, which are required to ensure adequate fluid resuscitation.

1.3.2 DYSENTRY (ACUTE INFLAMMATORY DIARRHOEA)

Antibiotic therapy: *Editorial amendment*

An editorial amendment with reference to culture and sensitivity results, was made to the STG as tabulated below:

Antibiotic therapy

Consider in patients with signs of sepsis and severe cases or significant underlying disease:

- Ceftriaxone, IV 1g daily.
  - Switch to oral therapy when clinically appropriate i.e. ciprofloxacin, oral, 500 mg 12 hourly, ideally based on culture and sensitivity if available.

1.3.3 DIARRHOEA, ACUTE NON-INFLAMMATORY

Medicine treatment –loperamide: *Dose amended*

The maximum daily dose of loperamide in adults has been amended in accordance with weight based dose banding included in the package insert[17]. Amendments are as tabulated below:

AMENDED FROM:

- Loperamide, oral, 4 mg immediately and 2 mg as required after each loose stool, up to 6 hourly.
  - Maximum daily dose: 12 mg.

AMENDED TO:

- Loperamide, oral, 4 mg immediately and 2 mg as required after each loose stool.
  - Maximum daily dose for adults: refer to dose table below.

Weight band	Maximum daily dose (equivalent maximum number of 2 mg tablets per day)
34-39 kg	10 mg (5 tablets)
40-46 kg	12 mg (6 tablets)
47-53 kg	14 mg (7 tablets)
≥ 54 kg	16 mg (8 tablets)

1.3.4 CLOSTRIDIUM DIFFICILE DIARRHOEA

Description: *Editorial amendment*

An editorial amendment was made to include *Clostridioides difficile* as an alternative description to *Clostridium difficile*, following its reclassification in 2016[18]. As labortatory reporting still refers to *Clostridium difficile*, this has been retained as the more commonly used description in the EML.

[17] Loperamide (max dose). Package Insert. Imodium. Johnson & Johnson (Pty) Ltd.. Renewal of authorisation 04 March 2005.

[18] The Lancet Infectious Diseases. C difficile-a rose by any other name…. Lancet Infect Dis. 2019 May;19(5):449. doi: 10.1016/S1473-3099(19)30177-X. Erratum in: Lancet Infect Dis. 2019 Jun;19(6):e187. PMID: 31034382.

Mild to moderate infection – vanomycin: *Not added*

Metronidazole is retained as the treatment option for the managaement of mild to moderate C.difficile infection in line with the previous NEMLC report published in 2018[19]. A summary of the NEMLC recommendation is tabulated below.

Recommendation:

Based on this review, the Adult Hospital Level Committee recommends that severe and recurrent CDI be treated as follow:

- *For severe cases:* Vancomycin parenteral administered orally and metronidazole, IV if unable to take oral treatment.
- *For recurring cases*: Pulse and tapered vancomycin therapy.

Rationale:

- Systematic review evidence showed no significant difference in the risk of mortality between treatment groups among patients with mild to moderate CDI, but vancomycin significantly reduced the risk of all-cause 30-day mortality among patients with **severe** CDI.
- Recommendations aligned with clinical practice guidelines for *Clostridium difficile* infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA), taking into consideration the costs of the medicines.

Level of Evidence: I Systematic review, Guidelines

Review indicator:

Evidence of efficacy	Evidence of harm	Price reduction
X		

VEN status:

Vital	Essential	Necessary
	X	

NEMLC MINUTES OF THE MEETING OF 27 SEPTEMBER 2018:

NEMLC accepted the evidence review and proposed recommendation at the NEMLC meeting of 27 September 2018

Fulminant infection – rectal vancomycin: *Not added*

The use of rectal vancomycin was not supported as not deemed appropriate for the Adult Hospital level of care.

B. EDITORIAL AMENDMENTS

The associated EML chapter has been subject to clinical editorial review following NEMLC ratification of the chapter. These amendments have been incorporated below.

1.1.1 BOWEL PREPARATIONS

AMENDED FROM:

Bowel preparation is essential for colonoscopy.

Split-dose (half the dose the night before and half the dose on the day of colonoscopy) bowel cleanser and a low residue diet should be commenced the day before.

GENERAL MEASURES

Health care professionals should provide both oral and written patient education instructions and emphasise the importance of adherence to the bowel preparation.

MEDICINE TREATMENT

Preparations containing ingredients such as polyethylene glycol (PEG), and sodium sulphate are adequate for bowel cleansing.

- PEG/sodium sulfate, oral, solution.
  - 2 litres the night before the procedure and 2 litres the following morning within two hours of the procedure.

Routine use of adjunctive agents (e.g. bisacodyl, senna, prokinetics) for

[19] NDoH evidence review: Antibacterials for enterocolitis due to Clostridium difficile. 5 April 2018

bowel cleansing before colonoscopy is not recommended

AMENDED TO:

DESCRIPTION

Bowel preparation is essential for colonoscopy.

GENERAL MEASURES

Health care professionals should provide both oral and written patient education instructions and emphasise the importance of adherence to the bowel preparation.

MEDICINE TREATMENT

Start bowel preparation as a split-dose regimen the day before the scheduled procedure: half the dose the night before and half the dose on the day of colonoscopy.
Commence a low residue diet the day before.

Preparations containing ingredients such as polyethylene glycol (PEG) and
sodium sulphate are adequate for bowel cleansing.

- PEG/sodium sulphate oral, solution:
  - Prescribe 2 litres the night before the procedure and 2 litres the following morning, two hours prior to the procedure.

Note:
Routine use of adjunctive agents (e.g. bisacodyl, senna, prokinetics) for bowel cleansing before colonoscopy is not recommended

1.1.2 DIVERTICULOSIS

AMENDED FROM:

<u>If unable to tolerate oral therapy:</u>

- Amoxicillin/clavulanic acid, IV, 1.2 g 8 hourly.

AMENDED TO:

<u>If unable to tolerate oral therapy:</u>

- Amoxicillin/clavulanic acid, IV, 1.2 g 8 hourly.
  - Switch to oral therapy once able to tolerate.

1.1.8 PEPTIC ULCER

AMENDED FROM:

DESCRIPTION

Ulcer in the stomach mucosa (gastric ulcer: GU) or first few centimetres of the duodenum (duodenal ulcer: DU), which penetrates into or through the muscularis mucosa.
Diagnosis is made after endoscopy, as all GUs require biopsy to exclude malignancy.
Patients with GUs and complicated DUs, those that have bled, perforated or are recurrent, must be rescoped at appropriate intervals until the ulcer has healed. *H. pylori* can be assessed at scope by rapid urease testing (RUT) or biopsy.

GENERAL MEASURES

Advise patient to avoid ulcerogenic medications, e.g. NSAIDs.
Advise patient to stop smoking and drinking alcohol.
Dietary advice by dietician

AMENDED TO:

DESCRIPTION

Ulcer in the stomach mucosa (gastric ulcer: GU) or first few centimetres of the duodenum (duodenal ulcer: DU), which penetrates into, or through the muscularis mucosa. Diagnosis is made after endoscopy as all GUs require biopsy to exclude malignancy.

GENERAL MEASURES

» Advise patient to avoid ulcerogenic medications, e.g. NSAIDs.
» Advise patient to stop smoking and drinking alcohol.
» Dietary advice by dietician.

» Patients with GUs and complicated DUs, those that have bled, perforated or are recurrent, must be rescoped at appropriate intervals until the ulcer has healed. *H. pylori* can be assessed at scope by rapid urease testing (RUT) or biopsy.

1.2.3 PORTAL HYPERTENSION AND CIRRHOSIS

AMENDED FROM:

GENERAL MEASURES

Ascites: sodium restriction, i.e. ≤ 2 g/day or ≤ 88 mmol/day.
Monitor weight regularly.
Encephalopathy: with acute HE, protein restrict otherwise 1–1.5 g/kg protein per day.
Exclude infection, high protein load, occult bleed, sedatives and electrolyte disturbances and hepatocellular carcinoma.
Variceal bleeding: endoscopic variceal ligation and/or immediate referral for advanced management.

MEDICINE TREATMENT

Ascites R18

- Diagnostic paracentesis if indicated
- Single morning dose of spironolactone, oral 100 mg and furosemide, oral, 40 mg.
  - Increase the dose by 100 mg and 40 mg, respectively, every 3–5 days, to a maximum dose of 400 mg spironolactone and 160 mg of furosemide depending on serum Na+, K+, urea and creatinine.
  - Spironolactone may cause hyperkalaemia.
  - Rapid fluid shifts may precipitate acute liver and/or renal failure.

Monitoring of sodium, potassium and renal function is essential in patients taking spironolactone. Avoid spironolactone if eGFR <30 mL/minute.

Measure response to diuretics by weighing patient daily. Aim for maximal weight loss of:

500 g/day	patients without oedema
1 000 g/day	patients with oedema

AMENDED TO:

GENERAL MEASURES

» Ascites: Perform diagnostic paracentesis if indicated. Restrict sodium intake, i.e. ≤ 2 g/day or ≤ 88 mmol/day.
» Monitor weight regularly.
» Encephalopathy: with acute HE, protein restrict (ideally under advice of dietician), otherwise 1–1.5 g/kg protein per day.
» Exclude infection, high protein load, occult bleed, sedatives, electrolyte disturbances and hepatocellular carcinoma.
» Variceal bleeding: endoscopic variceal ligation and/or immediate referral for advanced management.

MEDICINE TREATMENT

Ascites R18

- Spironolactone, oral, 100 mg daily.
  AND
- Furosemide, oral, 40 mg daily.

For spironolactone and furosemide:

- Increase spironolactone and furosemide dose by 100 mg and 40 mg, respectively, every 3–5 days, to a maximum dose of 400 mg spironolactone and 160 mg of furosemide depending on serum Na^+, K^+, urea and creatinine.
- Spironolactone may cause hyperkalaemia.
- Rapid fluid shifts may precipitate acute liver and/or renal failure.

Monitoring of sodium, potassium and renal function is essential in patients taking spironolactone. Avoid spironolactone if eGFR <30 mL/minute.

Measure response to diuretics by weighing patient daily. Aim for maximal weight loss of:
» Patients without oedema: 500 g/day
» Patients with oedema: 1 000 g/day

AMENDED FROM:

Oesophageal varices

To reduce the risk of bleeding:

- Beta-blocker, e.g.:
- Propranolol, oral, 20–40 mg 12 hourly. Titrate to resting pulse rate of 55-60 beats per minute (bpm). Monitor pulse and BP.

AMENDED TO:

Oesophageal varices I85.0/I85.9

To reduce the risk of bleeding:

- Beta-blocker, e.g.:
- Propranolol, oral, 20–40 mg 12 hourly. Titrate to resting pulse rate of 50–60 beats per minute. Monitor pulse and BP

1.2.4.1 HEPATITIS B, ACUTE

AMENDED FROM:

Hepatitis B virus: prophylaxis following exposure e.g. needle stick injury

S61.0 + (W46.22+Z20.5+Z29.8)

Persons at risk can be protected by passive immunisation with hyper immune serum globulin prepared from blood containing anti-HBs.

It is essential that all categories of healthcare workers (HCW) at risk of contact with bodily fluids , including cleaning staff, home-based or family caregivers are screened and fully vaccinated against hepatitis B if non-immune.

All exposure incidents must be adequately documented for possible subsequent compensation.

Recommended post-exposure management for HCW exposed to infectious material from patients with infectious hepatitis B (either surface antigen or e antigen positive).

Vaccination status and antibody response status of HCW	**Source patient status & treatment**		
	HBsAg positive	**HBsAg negative**	**HBsAg unknown**
Unvaccinated **OR** vaccination incomplete	• HBIG, IM, 500 units* • Hep B vaccine (3 doses at monthly intervals)	• Initiate Hep B vaccination (month 0, 1 and 6)	• HBIG, IM, 500 units* • Hep B vaccine (3 doses at monthly intervals)
Vaccinated AND HBsAb >10 units/mL#	No treatment	No treatment	No treatment
Vaccinated **AND** HBsAb <10 units/mL	• HBIG, IM, 500 units * • Repeat Hep B vaccine (3 doses at monthly intervals)	• Initiate Hep B vaccination (month 0, 1 and 6)	• HBIG, IM, 500 units* • Repeat Hep B vaccine (3 doses at monthly intervals)

* HBIG and first dose of vaccine to be given simultaneously, but at different sites.

If the delay in obtaining HBsAb results is more than 24 hours initiate treatment as for vaccinated AND HBsAb <10 units/mL.

AMENDED TO:

Hepatitis B virus: prophylaxis following exposure e.g. needle stick injury

S61.0 + (W46.22+Z20.5+Z29.8)

» Persons at risk can be protected by passive immunisation with hyper immune serum globulin prepared from blood containing anti-HBs.

» It is essential that all categories of healthcare workers (HCW) at risk of contact with bodily fluids, including cleaning staff and home-based or family caregivers, are screened and fully vaccinated against hepatitis B if nonimmune.

» All occupational exposure incidents must be adequately documented for possible subsequent compensation.

» Recommended post-exposure management for HCW exposed to infectious material from patients with infectious hepatitis B (either surface antigen or e antigen positive).

Check vaccination status and antibody response of HCW (See table below for management depending on immunity

Vaccination status and antibody response status of HCW	**Source patient status & treatment**		
	HBsAg positive	**HBsAg negative**	**HBsAg unknown**
Unvaccinated **OR** vaccination incomplete	• HBIG, IM, 500 units* • Hep B vaccine (3 doses at monthly intervals)	• Initiate Hep B vaccination (month 0, 1 and 6)	• HBIG, IM, 500 units* • Hep B vaccine (3 doses at monthly intervals)
Vaccinated **AND** HBsAb ≥10 units/mL#	No treatment	No treatment	No treatment
Vaccinated **AND** HBsAb <10 units/mL	• HBIG, IM, 500 units * • Repeat Hep B vaccine (3 doses at monthly intervals)	• Initiate Hep B vaccination (month 0, 1 and 6)	• HBIG, IM, 500 units* • Repeat Hep B vaccine (3 doses at monthly intervals)

* HBIG and first dose of vaccine to be given simultaneously, but at different sites.

If the delay in obtaining HBsAb results is more than 24 hours initiate treatment as for vaccinated AND HBsAb <10 units/mL.

Table 1.1: Prophylaxis following Hepatitis B exposure

AMENDED FROM:

Treat all patients with cirrhosis regardless of ALT level, HBeAg status and DNA level, to prevent hepatitis B flares that will lead to decompensation

AMENDED TO:

Treat all patients with cirrhosis regardless of ALT level, HBeAg status and HBV viral load, to prevent hepatitis B flares that will lead to decompensation.

1.2.4.4 HEPATITIS C, CHRONIC

Acute liver failure

Consult a specialist.

1.3.2 DYSENTRY (ACUTE INFLAMMATORY DIARRHOEA)

AMENDED FROM:

GENERAL MEASURES

Rehydration is the cornerstone of management. This should be done with oral rehydration solution (ORS) unless the patient is vomiting or profoundly dehydrated.

Stool culture is advised.

AMENDED TO:

GENERAL MEASURES

» Rehydration is the cornerstone of management. This should be done with oral rehydration solution (ORS) unless the patient is vomiting or profoundly dehydrated.

» Perform a stool culture.

AMENDED FROM:

Antibiotic therapy

Consider in patients with signs of sepsis and severe cases or significant underlying disease:

- Ceftriaxone, IV 1g daily.
  - Switch to oral therapy when clinically appropriate i.e. ciprofloxacin, oral, 500 mg 12 hourly, ideally based on culture and sensitivity if available.

For uncomplicated dysentery in patients with no co-morbidity:

- Ciprofloxacin, oral, 500 mg 12 hourly for 3 days.

For uncomplicated dysentery in patients with significant co-morbidity e.g. immunocompromised patients:

- Ciprofloxacin, oral, 500 mg 12 hourly for 7 days.

AMENDED TO:

Antibiotic therapy

Consider in patients with signs of sepsis, severe cases, or significant underlying disease:

- Ceftriaxone, IV 1 g daily.

Switch antibiotic when clinically appropriate:

- Ciprofloxacin, oral, 500 mg 12 hourly, ideally based on culture and sensitivity if available.

For uncomplicated dysentery in patients with no co-morbidity:

- Ciprofloxacin, oral, 500 mg 12 hourly for 3 days.
  - Extend treatment duration to 7 days in patients with significant co-morbidity, e.g. immunocompromised patients.